Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Karolinska Development Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Karolinska Development şirketinin toplam hissedar öz sermayesi SEK1.2B ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK1.2B ve SEK13.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 49.72m
Eşitlik	SEK 1.23b
Toplam yükümlülükler	SEK 13.41m
Toplam varlıklar	SEK 1.24b

Son finansal sağlık güncellemeleri

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Aug 19

Recent updates

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

May 04

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Aug 19

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Apr 27

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

Feb 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: KDEV 'nin kısa vadeli varlıkları ( SEK63.2M ) kısa vadeli yükümlülüklerini ( SEK13.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: KDEV un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: KDEV borçsuzdur.

Borcun Azaltılması: KDEV şirketinin 5 yıl önce borç/öz sermaye oranı 177.6% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: KDEV şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: KDEV serbest nakit akışı her yıl % 2.1 2.1 yıl yetecek nakit akışına sahip olacaktır.

Karolinska Development Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Recent updates

An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

Third quarter 2023 earnings released: EPS: kr0.044 (vs kr0.17 loss in 3Q 2022)

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Price target decreased to kr5.40

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Second quarter 2022 earnings released

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Price target increased to kr7.90

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

CFO & Deputy CEO Fredrik Jarrsten has left the company

Karolinska Development AB Announces CFO Changes

Karolinska Development Appoints Johan Dighed as Deputy CEO

New 90-day low: kr1.59

Karolinska Development AB (publ) Announces Management Appointments

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

New 90-day low: kr1.61

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

New 90-day low: kr1.80

Investor sentiment deteriorated over the past week

New 90-day low: kr2.17

New 90-day low: kr2.31

New 90-day low: kr2.60

New 90-day low: kr2.61

Price target lowered to kr4.30

Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB.